drugset / Trial / NCT03459612

A Study of Lasmiditan on Simulated Driving Performance in Healthy Participants

NCT03459612

Phase 1 Completed 68 enrolled Eli Lilly and Company
RandomizedCrossoverDouble-blindBasic science

Summary

The purpose of this study is to evaluate the effect of lasmiditan on simulated driving performance in healthy participants. Participants are expected to complete each of four study periods, which will last a total of about 10 days. During this time, participants will remain in the clinical research unit. Screening must be completed within 28 days before the start of the study. Follow-up will be completed about one week after discharge.

Timeline

Start
2018-03-26
Primary completion
2018-06-23
Completion
2018-06-23

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diphenhydramine Unknown 50 mg Oral
Subject Lasmiditan Small molecule 100 mg Oral
Subject Lasmiditan Small molecule 200 mg Oral

Indications

No indication recorded.